ClinicalTrials.gg
CompletedNCT03004131Updated Feb 22, 2022

MP-AzeFlu Allergen Chamber - Onset of Action Study

A Phase 4 interventional study of Azelastine hydrochloride + fluticasone propionate nasal spray and Placebos in Seasonal Allergic Rhinitis, sponsored by MEDA Pharma GmbH & Co. KG. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-02-22.

Sponsored by MEDA Pharma GmbH & Co. KG (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.

Enrollment
12th of 16
82 · median 415
Started
2017
the only one that year
Phase 4
Only one
of the 16
Registered
12th of 16
by date
Lead sponsor
2 of 16
MEDA Pharma GmbH & Co. KG

Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one is the 12th largest by enrollment, is the only one that started in 2017, is the only one in phase 4, and was the 12th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About azelastine

azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Chamber (EEC).

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written .
  2. Male or female subjects (childbearing and non-, defined as females with no menstruation for a minimum of 12 months prior to screening) aged 18 to 55 years (inclusive) at screening.
  3. History of SAR to ragweed pollen for at least the previous 2 ragweed pollen seasons.
  4. Positive skin prick test (SPT) response to ragweed pollen (allergen induced wheal diameter at least 3 mm larger than the negative control). A test performed in the previous 12 months may be used to qualify the subject.

    To be eligible for Visit 2 EEC, a subject must additionally comply with the following criteria:

  5. Asymptomatic or with mild symptoms during the baseline recording of symptoms prior to start of the screening EEC (Visit 2):

    • TNSS ≤ 3/12 with the score for each symptom being less than 2.

    To be eligible for Visit 3, a subject must additionally comply with the following criteria during Visit 2 EEC:

  6. Demonstrate adequate symptomology:

    • TNSS ≥ 6/12 on at least two ePDAT™ time point assessments during hours 0-2 in the EEC (Visit 2), with at least one occurring during the last two time points. Additionally, subjects will be required to meet a score of at least 2/3 for runny nose at least twice during hours 0-2 in the EEC, with at least one occurring during the last two time points.

    To be eligible for randomisation (Visit 3), a subject must additionally comply with the following criteria:

  7. Demonstrate adequate symptomology:

    • TNSS ≥ 6/12 on at least two ePDAT™ time point assessments during hours 0-2 in the EEC (Visit 3), with at least one occurring during the last two time points. Additionally, subjects will be required to meet a score of at least 2/3 for runny nose at least twice during hours 0-2 in the EEC, with at least one occurring during the last two time points.
    • No evidence of complete nasal blockage on either one or both sides on anterior rhinoscopy within 30 minutes prior to dosing.

Exclusion criteria

Exclusion Criteria:

Safety concerns:

  1. History of allergic reaction to fluticasone propionate, azelastine hydrochloride, loratadine, or one of the of the study treatments (e.g. benzalkonium chloride, phenylethyl alcohol, microcrystalline cellulose) or a component of the container.
  2. History of anaphylaxis, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, psychiatric, neurological, or other disease at screening that may affect subject safety during the study or evaluation of the study endpoints at the discretion of the Investigator and/or designee.
  3. Subjects with a current diagnosis of asthma or subjects with measured \<75% of the predicted value.
  4. Pregnant, breast-feeding or planning a pregnancy during the study and women of not using adequate . Women of childbearing potential not abstinent or using a highly effective method of birth control defined as those which result in a low failure rate (i.e. \<1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner started at least 4 weeks prior to screening.

    Lack of suitability for the study:

  5. Previous and concomitant treatments: use of prohibited therapies (Antihistaminic agents,Theophylline, Cromolyn sodium, , Decongestants, Immunotherapy, Systemic antibiotics, any cytochrome P450 3A4 inhibiting or inducing drug [e.g. ritonavir, ketoconazole, itraconazole, erythromycin, cimetidine, rifampicin, St. John's wort (Hypericum perforatum) etc.], Tricyclic antidepressants and MAO inhibitors ); and use of any medication considered to have an influence on the outcome of the study during the EEC session, at the discretion of the Investigator and/or designee.
  6. Subjects with (expected) symptoms at the timing of the scheduled EEC assessments due to concomitant sensitization, i.e., positive SPT (mean wheal diameter at least 3 mm larger than the negative control) and a history of allergic response to the causative allergen, at the discretion of the Investigator. Subjects with a positive SPT for cats and/or dogs are acceptable if the subject avoids cats and/or dogs for the duration of the study.
  7. Concomitant diseases: abnormalities during the screening visit that might interfere with study results as determined by the Investigator and/or designee.
  8. Presence of a severely deviated septum, septal perforation, structural nasal defect or large nasal polyps causing obstruction as determined by the Investigator.
  9. Acute conditions: any acute illness within 7 days prior to the screening visit, including acute conjunctivitis or any other ocular infection.
  10. History of increased ocular pressure, glaucoma and/or cataracts.
  11. Tuberculosis, untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections or ocular herpes simplex.
  12. Recent nasal ulcers, mucosal erosion, nasal surgery, or nasal trauma, as judged by the Investigator.
  13. Exposure to chickenpox or measles within 4 weeks prior to the screening visit or during the study.
  14. History of chronic sinusitis or history of non-allergic rhinitis.
  15. Exposure to another product within the last 30 days prior to screening.
  16. History of within the past five years, except for basal cell skin carcinomas that have been treated with no recurrence for at least 3 months.
  17. Neurological or psychiatric disease or drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment. Subjects with a positive urine drug screen will be excluded.
  18. Subjects undergoing surgical procedures with general anaesthesia within 90 days prior to screening or who plan to undergo surgery/hospitalization during the study.

    Administrative reasons:

  19. Vulnerable subjects (such as persons kept in detention).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    fixed drug combination

    MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet

    Drug: Azelastine hydrochloride + fluticasone propionate nasal spray

  • Placebo comparator
    Placebo

    Nasal spray with no active dose plus Placebo tablet

    Drug: Placebos

  • Active comparator
    active control

    fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)

    Drug: fluticasone propionate nasal spray + loratadine

Interventions

06

What researchers measure

Primary outcomes

  1. Total Nasal Symptom Score (TNSS); change from baseline over the last 4 hours of exposure in an Environmental Exposure Chamber (EEC)

    Time frame: Onset of action (first significant difference to placebo) up to 4 hours.

07

Study locations

1 site
  • Inflamax Research
    Mississauga, Ontario L4W1Ae, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Mar 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2016
First posted
Dec 28, 2016
StartActual
Jan 7, 2017
Primary completionActual
Mar 29, 2017
CompletionActual
Mar 29, 2017
Last update
Feb 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03004131
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Jan 7, 2017
Primary completion
Mar 29, 2017
Completion
Mar 29, 2017
Last update
Feb 22, 2022

Study contacts

Christine Kolb
study director · MEDA Pharma GmbH & Co. KG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azelastine · Fluticasone

Start the discussion